NeuroTau

NeuroTau is a clinical-stage biotechnology company based in Warwick, Rhode Island, focused on developing disease-modifying therapies for neurodegenerative disorders and tauopathies. The company's proprietary approach involves the modulation of the transcription factor Specificity Protein 1 (Sp1), which regulates the expression of key pathogenic proteins including Tau and Amyloid Precursor Protein (APP). NeuroTau's lead program, Tolfenamic acid, is currently in Phase 2 clinical development for Progressive Supranuclear Palsy (PSP), a rare and fatal neurodegenerative condition. The company's pipeline also features preclinical candidates NTX-341 and NTX-721, which target Sp1 and GSK-3β for the treatment of Alzheimer's disease and Huntington's disease. By intervening at the transcriptional level, NeuroTau aims to reduce the production of toxic protein aggregates and slow disease progression.